B. Sh. Kamolov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
B. Sh. Kamolov has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Vsevolod Borisovich Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
6 shared publications - Andrey A. Kirichek
Moscow City Oncological Hospital No. 62, Moscow Healthcare Department
3 shared publications - F. A. Kossov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - I. I. Abdullin
European Medical Center
2 shared publications - V. O. Panov
Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
2 shared publications - A. S. Markova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication
Latest Publications
- Open Access
- 1 June 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (1) , 75-80
Problems in preparation of legally binding documents for oncological and palliative patients and their solutions
Introduction. Oncological and palliative patients undergo treatment causing adverse events including mental and cognitive disorders leading to their inability to express their wishes in the legal sense. This affects the possibility of preparation of documents on disposal of property: wills, donation or sale and purchase agreements, letters of authorization.Aim. To consider problems arising when an oncological or palliative patient decides to dispose of their property and to suggest solutions to these problems.Materials and methods. An analysis of the current normative legal acts and legal precedents in the Russian Federation in the context of property disposal by severely ill patients was performed. Clinical guidelines on treatment of chronic pain in oncological and palliative patients, as well as Russian and international approaches to this therapy were considered.Results. Legal solutions for the considered problem appear to lack effectiveness. Use of tafalgin in treatment of severely ill patients can decrease risks and ease the process of preparation of documents on property disposal. This medication is indicated for chronic pain syndrome and unlike other pharmaceuticals is not an opioid analgesic and does not have severe side effects. Administration of tafalgin allows patients to retain mental clarity and avoid the risk of physical and psychological addiction.Conclusion. It is necessary to continue the search for new therapeutic approaches to chronic pain treatment taking into account needs and special aspects of oncological and palliative patients which would allow them to preserve full legal competency and dispose of their property without legal risks.
- 1 June 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (1) , 75-80
Open AccessProblems in preparation of legally binding documents for oncological and palliative patients and their solutions
Introduction. Oncological and palliative patients undergo treatment causing adverse events including mental and cognitive disorders leading to their inability to express their wishes in the legal sense. This affects the possibility of preparation of documents on disposal of property: wills, donation or sale and purchase agreements, letters of authorization.Aim. To consider problems arising when an oncological or palliative patient decides to dispose of their property and to suggest solutions to these problems.Materials and methods. An analysis of the current normative legal acts and legal precedents in the Russian Federation in the context of property disposal by severely ill patients was performed. Clinical guidelines on treatment of chronic pain in oncological and palliative patients, as well as Russian and international approaches to this therapy were considered.Results. Legal solutions for the considered problem appear to lack effectiveness. Use of tafalgin in treatment of severely ill patients can decrease risks and ease the process of preparation of documents on property disposal. This medication is indicated for chronic pain syndrome and unlike other pharmaceuticals is not an opioid analgesic and does not have severe side effects. Administration of tafalgin allows patients to retain mental clarity and avoid the risk of physical and psychological addiction.Conclusion. It is necessary to continue the search for new therapeutic approaches to chronic pain treatment taking into account needs and special aspects of oncological and palliative patients which would allow them to preserve full legal competency and dispose of their property without legal risks.
- Open Access
- 25 July 2021
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 17 (2) , 83-92-92
Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists
Background. Despite the recent amendments to the guidelines for the treatment of metastatic hormone-sensitive prostate cancer (PCa) implying standard use of luteinizing hormone-releasing hormone (LHRH) agonists in combination with chemotherapy or androgen inhibitors, androgen deprivation therapy (ADT) remains an essential component of treatment for advanced PCa. Testosterone target castration level of 20 ng/dL implies routine measurement of testosterone levels along with prostate-specific antigen (PSA) levels during ADT. It is particularly interesting to evaluate the frequency of achieving castration testosterone level in routine clinical practice. Objective: to assess the frequency of achieving castration testosterone level (20 ng/dL) and maintaining it after 6 months of therapy in patients with hormone-sensitive PCa receiving an LHRH agonist for the first time. Materials and methods. In 2019-2020, Russian Society of Cancer Urologists conducted a non-interventional prospective multicenter study (observational program) aimed to evaluate the efficacy of LHRH agonist (including buserelin, goserelin, leuprorelin or triptorelin) in routine clinical practice in Russia. This study involved 39 cancer urologists and 479 patients aged 18 years and older diagnosed with hormone-sensitive PCa, who started their ADT with LHRH agonists for the first time regardless of the disease stage and previous treatment. Patients received hormone therapy with an LHRH agonist for at least 6 months, visiting their doctor every 3 months (visit 1; visit 2: after 3 months; visit 3: after 6 months). Results. Patients received one of the following drugs: leuprorelin (3.75 mg; 7.5 mg; 22.5 mg; 45 mg; n = 225; 47,0 %), goserelin (3.6 mg; 10.8 mg; n = 132; 27.5 %), buserelin (3.75 mg; n = 67; 14.0 %), and triptorelin (3.75 mg; 11.25 mg; n = 55; 11.5 %). Of 479 patients, 186 (38.8 %) received combination treatment with bicalutamide, 12 (2.5 %) with fluta-mide, 54 (11.3 %) with zoledronic acid, and 11 (2.3 %) with denosumab. Among 146 patients with metastatic PCa, a combination of ADT plus docetaxel was administered to 30 participants (20.6 %), ADT plus abiraterone to 8 participants (5.5 %), and ADT plus enzalutamide to 2 participants (1.4 %). After 6 months of therapy, mean PSA level decreased by 94.2 % (from baseline 118.12 ng/mL to 6.87 ng/mL). Mean testosterone level was 19.0 ng/dL (range: 0.029-100 ng/dL). Among 430 patients, the targeted testosterone level 50 ng/dL. The incidence of adverse events was low; most of them were mild. Conclusion. Our findings suggest that not all patients achieve targeted testosterone level of <20 ng/dL, which corroborates the need for routine monitoring of testosterone levels during therapy to ensure its timely correction. We observed frequent administration of ADT with maximum androgen blockade. In patients with metastatic PCa, the use of standards for combination treatment with docetaxel and androgen inhibitors is limited.
- 25 July 2021
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 17 (2) , 83-92-92
Open AccessLuteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists
Background. Despite the recent amendments to the guidelines for the treatment of metastatic hormone-sensitive prostate cancer (PCa) implying standard use of luteinizing hormone-releasing hormone (LHRH) agonists in combination with chemotherapy or androgen inhibitors, androgen deprivation therapy (ADT) remains an essential component of treatment for advanced PCa. Testosterone target castration level of 20 ng/dL implies routine measurement of testosterone levels along with prostate-specific antigen (PSA) levels during ADT. It is particularly interesting to evaluate the frequency of achieving castration testosterone level in routine clinical practice. Objective: to assess the frequency of achieving castration testosterone level (20 ng/dL) and maintaining it after 6 months of therapy in patients with hormone-sensitive PCa receiving an LHRH agonist for the first time. Materials and methods. In 2019-2020, Russian Society of Cancer Urologists conducted a non-interventional prospective multicenter study (observational program) aimed to evaluate the efficacy of LHRH agonist (including buserelin, goserelin, leuprorelin or triptorelin) in routine clinical practice in Russia. This study involved 39 cancer urologists and 479 patients aged 18 years and older diagnosed with hormone-sensitive PCa, who started their ADT with LHRH agonists for the first time regardless of the disease stage and previous treatment. Patients received hormone therapy with an LHRH agonist for at least 6 months, visiting their doctor every 3 months (visit 1; visit 2: after 3 months; visit 3: after 6 months). Results. Patients received one of the following drugs: leuprorelin (3.75 mg; 7.5 mg; 22.5 mg; 45 mg; n = 225; 47,0 %), goserelin (3.6 mg; 10.8 mg; n = 132; 27.5 %), buserelin (3.75 mg; n = 67; 14.0 %), and triptorelin (3.75 mg; 11.25 mg; n = 55; 11.5 %). Of 479 patients, 186 (38.8 %) received combination treatment with bicalutamide, 12 (2.5 %) with fluta-mide, 54 (11.3 %) with zoledronic acid, and 11 (2.3 %) with denosumab. Among 146 patients with metastatic PCa, a combination of ADT plus docetaxel was administered to 30 participants (20.6 %), ADT plus abiraterone to 8 participants (5.5 %), and ADT plus enzalutamide to 2 participants (1.4 %). After 6 months of therapy, mean PSA level decreased by 94.2 % (from baseline 118.12 ng/mL to 6.87 ng/mL). Mean testosterone level was 19.0 ng/dL (range: 0.029-100 ng/dL). Among 430 patients, the targeted testosterone level 50 ng/dL. The incidence of adverse events was low; most of them were mild. Conclusion. Our findings suggest that not all patients achieve targeted testosterone level of <20 ng/dL, which corroborates the need for routine monitoring of testosterone levels during therapy to ensure its timely correction. We observed frequent administration of ADT with maximum androgen blockade. In patients with metastatic PCa, the use of standards for combination treatment with docetaxel and androgen inhibitors is limited.
- Open Access
- 30 March 2019
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 15 (1) , 57-65-65
The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer
Background.New potential biomarker for patients with metastatic hormone-naive prostate cancer (PCa) might be detection of programmed death ligand 1 (PD-L1) expression in tumor which is associated with worsened results of treatment and decreased survival in patients with pancreatic cancer, lung cancer and other malignant tumors.Objective: to evaluate the prognostic value of positive tumor PD-L1 status on time to castration resistance (CRPCa) in patients with metastatic PCa receiving hormonal androgen deprivation therapy in first-line systemic treatment.Materials and methods.A total of 35patients with metastatic hormone-naive PCa receiving androgen deprivation therapy with luteinizing hormone-releasing hormone analogue and follow-up at N.N. Blokhin National Medical Research Center of Oncology were recruited in our prospective study. Tumor features of all patients were evaluated for PD-L1 expression on tumor cells by immunohistochemical studies of paraffin block sections obtained under the visual control of the pathologist using a set of monoclonal anti-PD-L1 antibody (28-8) (ab 205921) and Ventana BenchMark GXSlide staining system. Tumor tissue was obtained before starting androgen deprivation therapy. The expression level of PD-L1 1 % in tumor cells was taken for the positive tumor PD-L1(+) status.Results. Median follow-up was 32.8 months. Positive tumor PD-L1(+) status was identified in 10 (28.6 %) cases. Median time to CRPCa was significantly lower in patients with PD-L1(+) status, than in negative PD-L1(—) status (21.44 vs. 49.12, p = 0.006 log rank test). Multivariate Cox regression analysis confirmed independence prognostic value of PD-L1(+) associated with decreased time to CRPCa (hazard ration 5.95, 95 % confidence interval 1.97—17.99; p = 0.002), including in subgroup of patients with low-volume metastatic disease (hazard ration 7.33, 95 % confidence interval 1.81—29.60; p = 0.005).Discussion. Interaction of PD-1 receptors and its ligands PD-L1/PD-L2 is the key mechanism causing tumor immune escape and progression of the cancer. There are discussed certain ways of inducing PD-L1 expression and its prognostic value on aggressive nonmetastatic PCa. High frequency of positive PD-L1 status was revealed in rare histological subtypes of PCa associated with unfavorable prognosis and visceral metastasis.Conclusion.The results of our study demonstrated the positive tumor PD-L1 status as an independent unfavorable prognostic factorfor patients with metastatic hormone-naive PCa associated with decreased time to castration resistance, including in patients with low volume metastatic disease.
- 30 March 2019
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 15 (1) , 57-65-65
Open AccessThe prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer
Background.New potential biomarker for patients with metastatic hormone-naive prostate cancer (PCa) might be detection of programmed death ligand 1 (PD-L1) expression in tumor which is associated with worsened results of treatment and decreased survival in patients with pancreatic cancer, lung cancer and other malignant tumors.Objective: to evaluate the prognostic value of positive tumor PD-L1 status on time to castration resistance (CRPCa) in patients with metastatic PCa receiving hormonal androgen deprivation therapy in first-line systemic treatment.Materials and methods.A total of 35patients with metastatic hormone-naive PCa receiving androgen deprivation therapy with luteinizing hormone-releasing hormone analogue and follow-up at N.N. Blokhin National Medical Research Center of Oncology were recruited in our prospective study. Tumor features of all patients were evaluated for PD-L1 expression on tumor cells by immunohistochemical studies of paraffin block sections obtained under the visual control of the pathologist using a set of monoclonal anti-PD-L1 antibody (28-8) (ab 205921) and Ventana BenchMark GXSlide staining system. Tumor tissue was obtained before starting androgen deprivation therapy. The expression level of PD-L1 1 % in tumor cells was taken for the positive tumor PD-L1(+) status.Results. Median follow-up was 32.8 months. Positive tumor PD-L1(+) status was identified in 10 (28.6 %) cases. Median time to CRPCa was significantly lower in patients with PD-L1(+) status, than in negative PD-L1(—) status (21.44 vs. 49.12, p = 0.006 log rank test). Multivariate Cox regression analysis confirmed independence prognostic value of PD-L1(+) associated with decreased time to CRPCa (hazard ration 5.95, 95 % confidence interval 1.97—17.99; p = 0.002), including in subgroup of patients with low-volume metastatic disease (hazard ration 7.33, 95 % confidence interval 1.81—29.60; p = 0.005).Discussion. Interaction of PD-1 receptors and its ligands PD-L1/PD-L2 is the key mechanism causing tumor immune escape and progression of the cancer. There are discussed certain ways of inducing PD-L1 expression and its prognostic value on aggressive nonmetastatic PCa. High frequency of positive PD-L1 status was revealed in rare histological subtypes of PCa associated with unfavorable prognosis and visceral metastasis.Conclusion.The results of our study demonstrated the positive tumor PD-L1 status as an independent unfavorable prognostic factorfor patients with metastatic hormone-naive PCa associated with decreased time to castration resistance, including in patients with low volume metastatic disease.
- Open Access
- 30 December 2018
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (4) , 16-21
A joint determination of gene expression and methylation for the diagnosis of clear cell renal cancer
Background. Clear cell renal cell carcinoma is the most frequent and most aggressive kidney cancer. Approximately 30 % at the initial diagnosis reveal distant metastases. This is due to the fact that kidney cancer in the early stages is asymptomatic. Very often (about 50 %), kidney cancer is detected by chance, during a routine examination or during treatment for other reasons. In this regard, the development of new methods of early diagnosis of clear cell renal cell carcinoma is actual. Materials and methods. The levels of mRNA expression and methylation of a number of genes in the surgical material of paired samples (normal kidney tissue and tumor, 21 clinical cases) were studied. Quantitative determination of gene expression was performed using real-time polymerase chain reaction on a Step One Plus instrument (Applied Biosystems, USA) using TaqMan®Gene Expression Assays (Applied Biosystems, USA). High molecular DNA was isolated from tissue by phenol-chloroform extraction. Methyl-specific polymerase chain reaction was performed on a T100 Thermal Cycler amplifier (Bio-Rad, USA).Results. As a result of joint analysis of the levels of gene expression and methylation, a system of potentially diagnostic markers has been developed, including the determination of the expression of a number of protein coding genes and the hypermethylation of several miRNA genes in tumor samples. Simultaneous determination of expression and methylation allows for the correct identification of tumors as SCRV with a sensitivity of 95.24 % (95 % confidence interval 76.18–99.88 %) and specificity of 95.24 % (95 % confidence interval 76.18–99.88 %). Conclusion. According to the results of the study, a system was developed based on the determination of the expression levels of the CA9, HIG2, EGLN3, NDUF4L2 genes and the methylation of the MIR9-1, MIR34b/c, MIR124a-3, MIR129-2. Depending on the requirements for sensitivity, reliability of determination, or ease of implementation, various combinations of these genes are possible.
- 30 December 2018
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (4) , 16-21
Open AccessA joint determination of gene expression and methylation for the diagnosis of clear cell renal cancer
Background. Clear cell renal cell carcinoma is the most frequent and most aggressive kidney cancer. Approximately 30 % at the initial diagnosis reveal distant metastases. This is due to the fact that kidney cancer in the early stages is asymptomatic. Very often (about 50 %), kidney cancer is detected by chance, during a routine examination or during treatment for other reasons. In this regard, the development of new methods of early diagnosis of clear cell renal cell carcinoma is actual. Materials and methods. The levels of mRNA expression and methylation of a number of genes in the surgical material of paired samples (normal kidney tissue and tumor, 21 clinical cases) were studied. Quantitative determination of gene expression was performed using real-time polymerase chain reaction on a Step One Plus instrument (Applied Biosystems, USA) using TaqMan®Gene Expression Assays (Applied Biosystems, USA). High molecular DNA was isolated from tissue by phenol-chloroform extraction. Methyl-specific polymerase chain reaction was performed on a T100 Thermal Cycler amplifier (Bio-Rad, USA).Results. As a result of joint analysis of the levels of gene expression and methylation, a system of potentially diagnostic markers has been developed, including the determination of the expression of a number of protein coding genes and the hypermethylation of several miRNA genes in tumor samples. Simultaneous determination of expression and methylation allows for the correct identification of tumors as SCRV with a sensitivity of 95.24 % (95 % confidence interval 76.18–99.88 %) and specificity of 95.24 % (95 % confidence interval 76.18–99.88 %). Conclusion. According to the results of the study, a system was developed based on the determination of the expression levels of the CA9, HIG2, EGLN3, NDUF4L2 genes and the methylation of the MIR9-1, MIR34b/c, MIR124a-3, MIR129-2. Depending on the requirements for sensitivity, reliability of determination, or ease of implementation, various combinations of these genes are possible.
- 9 October 2018
- Published by Bionika Media in Urologiia
- Vol. 4_2018 (4) , 106-112
Use of multiparametric magnetic resonance imaging in t-staging of prostate cancer: a multicenter study
The study aimed to analyze the diagnostic performance of preoperative multiparametric magnetic resonance imaging (mp-MRI) in the staging of prostate cancer (PCa) versus postoperative histological examination and determine the most sensitive pulse sequence from the mp-MRI protocol in estimating the local extent of PCa. The study comprised 112 men aged 52 to 84 years with a morphologically verified diagnosis of prostate cancer. All patients underwent pelvic mp-MRI before radical prostatectomy (RPE) no earlier than six weeks after the prostate biopsy. Radical prostatectomy was performed within two weeks after mp-MRI. MP-MRI findings and the results of postoperative histology were compared using a binary logistic regression model. The sensitivity, specificity, diagnostic accuracy, positive (PPV) and negative (NPV) predictive values for predicting extracapsular extension were 87.5, 92.6, 91, 84 and 94.3%, respectively; for predicting seminal vesicles invasion, they were 85, 95, 90, 80.9 and 96.7%, respectively. When stratified by the presence or absence of the pseudocapsule invasion, the reliability of detecting the tumor spread for different types of images decreases in the following order: DWI - T2 + DWI - T2 VI - DCE-MRI. mp-MRI has high sensitivity, specificity, general diagnostic accuracy, high NPV, and PPV values in detecting an extracapsular extension of prostate cancer. According to the binary logistic regression model, the greatest contribution to the decision on the presence or absence of extracapsular extension is also made by the DWI.
- 9 October 2018
- Published by Bionika Media in Urologiia
- Vol. 4_2018 (4) , 106-112
Use of multiparametric magnetic resonance imaging in t-staging of prostate cancer: a multicenter study
The study aimed to analyze the diagnostic performance of preoperative multiparametric magnetic resonance imaging (mp-MRI) in the staging of prostate cancer (PCa) versus postoperative histological examination and determine the most sensitive pulse sequence from the mp-MRI protocol in estimating the local extent of PCa. The study comprised 112 men aged 52 to 84 years with a morphologically verified diagnosis of prostate cancer. All patients underwent pelvic mp-MRI before radical prostatectomy (RPE) no earlier than six weeks after the prostate biopsy. Radical prostatectomy was performed within two weeks after mp-MRI. MP-MRI findings and the results of postoperative histology were compared using a binary logistic regression model. The sensitivity, specificity, diagnostic accuracy, positive (PPV) and negative (NPV) predictive values for predicting extracapsular extension were 87.5, 92.6, 91, 84 and 94.3%, respectively; for predicting seminal vesicles invasion, they were 85, 95, 90, 80.9 and 96.7%, respectively. When stratified by the presence or absence of the pseudocapsule invasion, the reliability of detecting the tumor spread for different types of images decreases in the following order: DWI - T2 + DWI - T2 VI - DCE-MRI. mp-MRI has high sensitivity, specificity, general diagnostic accuracy, high NPV, and PPV values in detecting an extracapsular extension of prostate cancer. According to the binary logistic regression model, the greatest contribution to the decision on the presence or absence of extracapsular extension is also made by the DWI.
- Open Access
- 30 September 2018
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (3) , 143-148-148
REVIEW OF THE ONCOLOGICAL UROLOGY PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2018 ANNUAL MEETING
The 54th American Society of Clinical Oncology (ASCO) Annual Meeting took place between 1st and 5th June in Chicago (USA) united more than 40,700 professionals of various fields. Oncological urology topics account for a considerable proportion of the Annual Meeting proceedings. In this article, a review of the most significant reports on cancer urology from the ASCO 2018 Annual Meeting is presented.
- 30 September 2018
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (3) , 143-148-148
Open AccessREVIEW OF THE ONCOLOGICAL UROLOGY PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2018 ANNUAL MEETING
The 54th American Society of Clinical Oncology (ASCO) Annual Meeting took place between 1st and 5th June in Chicago (USA) united more than 40,700 professionals of various fields. Oncological urology topics account for a considerable proportion of the Annual Meeting proceedings. In this article, a review of the most significant reports on cancer urology from the ASCO 2018 Annual Meeting is presented.
- Open Access
- 30 March 2018
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (1) , 166-172-172
On staging of urologic cancers in accordance with the updated 8th edition of the TNM Classification
On January 1, 2018, an updated 8th edition of the international TNM Classification of Malignant Tumors comes into effect. The classification was developed by 2 leading organizations: the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). Based on consensus conferences of the International Society for Urological Pathology (ISUP) which reconsidered the current approaches to pathomorphology and staging of malignant tumors of the prostate (2009), kidneys (2012), testicles and penis (2015), the World Health Organization approved the new morphological classification of tumors of the urinary and male reproductive systems. At the first time, the TNM Classification indicates evidence level.
- 30 March 2018
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (1) , 166-172-172
Open AccessOn staging of urologic cancers in accordance with the updated 8th edition of the TNM Classification
On January 1, 2018, an updated 8th edition of the international TNM Classification of Malignant Tumors comes into effect. The classification was developed by 2 leading organizations: the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). Based on consensus conferences of the International Society for Urological Pathology (ISUP) which reconsidered the current approaches to pathomorphology and staging of malignant tumors of the prostate (2009), kidneys (2012), testicles and penis (2015), the World Health Organization approved the new morphological classification of tumors of the urinary and male reproductive systems. At the first time, the TNM Classification indicates evidence level.
- Open Access
- 1 January 2017
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 98 (6) , 327-336
CURRENT POSSIBILITIES OF RADIATION DIAGNOSIS OF PROSTATE CANCER
СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ЛУЧЕВОЙ ДИАГНОСТИКИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
- 1 January 2017
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 98 (6) , 327-336
Open AccessCURRENT POSSIBILITIES OF RADIATION DIAGNOSIS OF PROSTATE CANCER
СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ЛУЧЕВОЙ ДИАГНОСТИКИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
- 1 March 2005
- Published by Elsevier in European Urology Supplements
- Vol. 4 (3) , 179
708Bladder preserving treatment versus cystectomy in patients with invasive TCC
- 1 March 2005
- Published by Elsevier in European Urology Supplements
- Vol. 4 (3) , 179
708Bladder preserving treatment versus cystectomy in patients with invasive TCC